Johannes Schetelig

1 month ago | nature.com | Gabrielle Meyers |Mehdi Hamadani |Michael Martens |Haris Ali |Patrice Chevallier |Andrew Harris | +6 more

Correction to: Bone Marrow Transplantation https://doi.org/10.1038/s41409-023-02110-4, published online 25 September 2023In this article the funding support is correct within the paper but during the submission process, it appears that the wrong grant number was selected. This paper is a BMT CTN protocol only, and is not CIBMTR related. As such only the BMT CTN Grant number (U24HL138660) should be selected. The original article has been corrected.

Mar 18, 2024 | nature.com | Romain Guièze |Johannes Schetelig |Jakob Passweg |Jürgen Finke |Mutlu Arat |Friedrich Stölzel | +7 more

AbstractManagement of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the EBMT. Median age at allo-HCT was 56.2 years (interquartile range (IQR), 51.3–63.1). Median time from RT to allo-HCT was 6.9 months (IQR, 4.9–11) and 28 (42.4%) were in complete remission (CR).

Sep 25, 2023 | nature.com | Gabrielle Meyers |Mehdi Hamadani |Michael Martens |Haris Ali |Patrice Chevallier |Andrew Harris | +6 more

This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Data availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request....

Sep 21, 2023 | onclive.com | Johannes Schetelig

Johannes Schetelig, MD, MSc, head, Stem Cell Transplantation Unit, University Hospital TU Dresden, head, DKMS Clinical Trials Unit, discusses whether patients with active relapsed/refractory acute myeloid leukemia (AML) should receive remission induction chemotherapy prior to undergoing allogenic hematopoietic stem cell transplant (allo-HCT).

Sep 6, 2023 | targetedonc.com | Johannes Schetelig

Sep 6, 2023Johannes Schetelig, MD, MSc, discusses the sequencing of allogeneic stem cell transplant to achieve the best response in patients with acute myeloid leukemia/Johannes Schetelig, MD, MSc, discusses the sequencing of allogeneic stem cell transplant to achieve the best response in patients with acute myeloid leukemia (AML). Schetelig participated in a debate on this subject at the SOHO 2023 Annual Meeting.